a

3S Corporation is one of India’s leading stockist, exporter & wholesaler for Anti-cancer drug & Oncology medicines. We even supply & export Sex Enhancement Drugs, Cardiac & Anti Diabetic Medicines. We are a registered wholesaler & exporter for pharmaceutical products licensed by our FDA and Drug Controller in India. Our license number are 20-B/MZ6-23015 & 21-B/ MZ6-23016.

+(91)-(22)-42643060

3scorp.india@gmail.com
Andheri East, Mumbai - 400099, India.

DISCLAIMER

All the pharmaceutical products we offer are prescription drugs and should be used/taken under proper medical guidance and advice. Do not share the medicine with others, since they may be suffering from a problem that is not effectively treated by this drug. We are not an online pharmacy . We do not recommend any drug or give medical advice. We only express opinions and provide information. Whether a medication is right for you is a decision between you and the prescribing doctor. Kindly seek medical advice from a registered doctor 0r hospital/Institution before taking any of these medicines.

Monday - Saturday

10.00 - 19.00

+(91)-(22)-42643060

3scorp.india@gmail.com

Andheri East

Mumbai – 400099, India.

Pamidronate Disodium IV Infusion BP 30 mg & 60 mg

Description

Pamidronate Disodium  IV Infusion BP 30 mg & 60 mg is used in  treatment of moderate to severe hypercalcemia associated with malignancy with or without bone metastases; treatment of moderate to severe Paget disease of bone; treatment of osteolytic bone lesions of multiple myeloma and bone metastases of breast cancer in conjunction with standard chemotherapy.

3s corporation is Supplier,Exporter ,Wholesaler  for Pamidronate Disodium  IV Infusion BP 30 mg & 60 mg in India.

India has many manufacturers who manufacture Pamidronate Disodium  IV Infusion BP 30 mg & 60 mg .To know more contact us.

Additional Information

Moderate to Severe Hypercalcemia of Malignancy
Adults

IV For moderate, give 60 to 90 mg as an initial single-dose infusion over 2 to 24 h. For severe, give 90 mg as an initial single-dose infusion over 2 to 24 h. For retreatment, same as initial therapy, at least 7 days after initial dose.

Paget Disease
Adults

IV 30 mg/day as a 4-h infusion on 3 consecutive days for a total dose of 90 mg. For retreatment, same as initial therapy, when clinically indicated.

Osteolytic Bone Metastases of Breast Cancer
Adults

IV 90 mg as a 2-h infusion every 3 to 4 wk.

Osteolytic Bone Lesions of Multiple Myeloma
Adults

IV 90 mg as a 4-h infusion on a monthly basis.

Side Effects

Cardiovascular

Atrial fibrillation; atrial flutter; cardiac failure; hypertension; syncope; tachycardia.

CNS

Asthenia; anxiety; fatigue; headache; insomnia; paresthesia; psychosis; somnolence.

Dermatologic

Sweating.

Endocrine

Hypothyroidism.

GI

Abdominal pain; anorexia; constipation; diarrhea; dyspepsia; GI hemorrhage; nausea; stomatitis; vomiting.

Genitourinary

UTI; uremia; renal toxicity.

Hematologic-Lymphatic

Anemia; granulocytopenia; leukopenia; neutropenia; thrombocytopenia.

Lab Tests

Hypocalcemia; hypokalemia; hypomagnesemia; hypophosphatemia.

Local

Infusion-site reaction.

Musculoskeletal

Arthralgia; arthrosis; back pain; bone pain; musculoskeletal pain; myalgia; osteonecrosis primarily of the jaws.

Respiratory

Coughing; dyspnea; pleural effusion; rales; rhinitis; sinusitis; upper respiratory infection.

Miscellaneous

Edema; fever; metastases; moniliasis; pain; allergic manifestations (eg, hypotension, dyspnea, angioedema, anaphylactic shock) .

Pack Size